Parkway Holdings (P27.SG) is up 1.28% at $3.16 after racing to almost two-year high of $3.30 in early trade as Fortis’ entry as new major investor fuels hopes of stronger growth prospects for Singapore healthcare group, reported Dow Jones Newswires.
“This deal should enlarge the platform for both entities, and enable Parkway and Fortis to leverage on each other’s strengths,” says Citigroup, which has a “buy” call with $3.40 target; “synergies include co-sharing and integration of best medical expertise such as stem cell therapy and organ transplant.”



